Study M1049
Study name | Ho CSH 2023 |
Title | The utility of amino acid metabolites in the diagnosis of major depressive disorder and correlations with depression severity |
Overall design | The aim of this study was to assess serum amino acid metabolite changes between major depressive disorder (MDD) patients and healthy controls and their association with disease severity and diagnostic utility. In total, 70 MDD patients (MDD group) and 70 healthy controls (control group) matched in age, gender, and ethnicity were recruited for the study. For amino acid profiling, serum samples were analyzed by liquid chromatography-mass spectrometry. |
Study Type | Type1; |
Data available | Unavailable |
Organism | Human; |
Categories of depression | Depressive disorder; Depression; Depression; |
Criteria for depression | DSM-5 diagnosed MDD |
Sample size | 140 |
Tissue | Peripheral; Blood; Serum; |
Platform | MS-based; LC-MS: Agilent 1290 Infinity liquid chromatography system (Agilent Technologies, Santa Clara, CA, USA) with quadrupole-ion trap mass spectrometer (QTRAP 5500, AB Sciex, Olympia, DC, USA); |
PMID | |
DOI | |
Citation | Ho CSH, Tay GWN, Wee HN, et al. The utility of amino acid metabolites in the diagnosis of major depressive disorder and correlations with depression severity. Int J Mol Sci. 2023 Jan 23;24(3):2231. |
Metabolite |
